Clinical Trials Commence for Extended Warfarin Sensitivity Test
News Nov 11, 2008
Osmetech plc announces that it has now commenced clinical trials for an extended warfarin sensitivity test.
Osmetech obtained clearance from the US Food and Drug Administration (FDA) in July 2008 for its eSensor® Warfarin Sensitivity Test to be used as an aid in the identification of patients at risk for increased sensitivity to the widely used blood-thinning drug, warfarin.
The extended warfarin test incorporates a number of additional markers, including the CYP450 4F2 biomarker exclusively-licensed from Marshfield Clinic.
Following successful pre-clinical studies, clinical trials will be conducted at three sites with the results supporting the Company’s submission for 510(k) clearance to the FDA expected to be filed before the end of 2008 as previously disclosed.
James White, Chief Executive, Osmetech plc, said: "We are excited by the prospects of being able to provide what we believe will be the most comprehensive FDA-cleared test for warfarin sensitivity available in the marketplace, which will include our important and unique biomarker, 4F2.”
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018